Favorites and recent references stay on this device. No patient data is stored.
Choose the species
One selection filters the source overview, clinical facts, reports and dose calculator. Literature references are not species-filtered.
Choose one species for its overview and dose calculator, or all species to browse the full evidence.
Source overview
Recorded excerpts for one species. Each dose remains a separate source entry; no regimen is selected.
Choose one species to view its source overview. All-species evidence remains available below.
View full clinical evidence and sources ↓Clinical evidence
Pending clinical review (PROPOSED)Rule-based (RULE_BASED)— applies to the facts and dose entries in this species selection; individual source records retain their own status.
Indications1
LONGRANGE, when administered at the recommended dose volume of 1 mL per 110 lb (50 kg) body weight, is effective in the treatment and control of the following internal and external parasites of cattle: Gastrointestinal Roundworms Lungworms Bunostomum phlebotomum 4 – Adults and L Dictyocaulus viviparus – Adults Cooperia oncophora 4 – Adults and L Cooperia punctata 4 – Adults and L Cooperia surnabada 4 – Adults and L Grubs Haemonchus placei – Adults Hypoderma bovis Oesophagostomum radiatum – Adults Ostertagia lyrata – Adults Mites Ostertagia ostertagi 4 4 – Adults, L, and inhibited L Sarcoptes scabiei bovis var. Trichostrongylus axei 4 – Adults and L Trichostrongylus colubriformis – Adults
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34067-9 (INDICATIONS & USAGE SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Dose regimens1
This calculator performs arithmetic only on the sourced dosing field shown for each result — it does not verify the field's accuracy, does not select which field to use for a patient, and does not replace a veterinarian's order. Not for clinical use. Confirm every result against the primary source before dispensing.
Choose one species above to view its dose calculator.
Adverse effects200
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Accidental exposure64 reports
- Mydriasis47 reports
- Blindness39 reports
- Ataxia31 reports
- Vomiting24 reports
- Hypersalivation19 reports
- Temporary blindness14 reports
- Depression11 reports
- Impaired vision9 reports
- Death7 reports
- Anorexia6 reports
- Dilated pupils6 reports
Cat
- Lethargy (see also Central nervous system depression in Neurological)490 reports
- Vomiting469 reports
- Hypersalivation369 reports
- Application site hair loss305 reports
- Foaming at the mouth303 reports
- Drooling251 reports
- Ataxia225 reports
- Lack of efficacy (endoparasite) - tapeworm218 reports
- Not eating216 reports
- Lack of efficacy (endoparasite) - roundworm NOS205 reports
- Lack of efficacy (ectoparasite) - flea201 reports
- Accidental exposure176 reports
Pharmacokinetics1
Due to its unique formulation characteristics, when LONGRANGE is injected subcutaneously in the shoulder area of cattle, a polymeric PLGA matrix is formed. The biodegradable matrix solidifies in vivo to form an in situ forming gel, which allows a gradual release of eprinomectin from the formulation. The rate-limiting step is diffusion of the drug through the gel matrix. Because of its mechanism of release, absorption characteristics can be highly dependent upon the injection technique used and the corresponding surface to volume ratio of the gel. Clinical efficacy of avermectins and milbemycins is closely related to their pharmacokinetic behavior, and the time of parasite exposure to active drug concentrations is relevant to obtain optimal and persistent antiparasitic activity (Lanusse et al., 1997; Lifschitz et al., 1999; Lifschitz et al., 2004; Shoop et al., 1996). Lifschitz et al. (1999) indicated that plasma concentrations between 0.5 and 1 ng/mL would represent the minimal drug level required for optimal nematocidal activity, while others have suggested minimum levels of 1 to 2 ng/mL. Pharmacokinetic studies of LONGRANGE in cattle indicate that effective plasma levels remain for an extended period of time (at least 100 days). 1a Mean Eprinomectin BPlasma Concentration Versus Time Following a Single Subcutaneous Injection of LONGRANGE at a Dose Rate of 1 mg Eprinomectin per kg Body Weight in Beef Cattle
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34090-1 (CLINICAL PHARMACOLOGY SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Literature references17
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- A case of sporadic cutaneous T-cell lymphosarcoma in a 3-year-old Holstein cow.
Study summary not available in the imported record. Open the original citation to review the study.
- Eprinomectin Inhibits Leishmania by Inducing Mitochondrial Dysfunction and Cell Cycle Arrest.
Study summary not available in the imported record. Open the original citation to review the study.
- Efficacy of NexGard® combo (esafoxolaner-eprinomectin-praziquantel) against natural Mammomonogamus ierei infection in cats.
Study summary not available in the imported record. Open the original citation to review the study.
- Efficacy of single and double doses of pour-on eprinomectin on small ruminant farms - Is it affected by Haemonchus contortus?
Study summary not available in the imported record. Open the original citation to review the study.
- Inherent P-glycoprotein deficiency and macrocyclic lactone toxicity in an Australian Maine Coon cat homozygous for ABCB11930_1931del TC.
Study summary not available in the imported record. Open the original citation to review the study.
Sources: DailyMed, U.S. National Library of Medicine; PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration.
Available products
Products listed in the Health Canada Drug Product Database for this active ingredient. A listing does not establish that a product is authorized for the clinical uses described on this page.